GLP-1s After Menopause: Weight, Visceral Fat, and Heart Risk

After the final period, the redistribution has already happened

This guide is about the years after your final period. (If you're still cycling, our companion on perimenopausal weight is the better fit — it covers the body-composition changes as they happen and the contraception questions that still apply there.)

Elena Voss is a mother writing for mothers, not a treating clinician, and holds no medical license. Every clinical figure here is cited inline to its primary source, the trial or the FDA label, so you can check it. This is background reading, not medical advice.

Two facts frame everything else on this page. The first is that the change is largely finished. In the SWAN cohort's DXA data, the accelerated fat gain and lean-mass loss that begin at the transition continue until roughly two years after the final menstrual period — and then the trajectories decelerate to zero slope¹. Post-menopause, you are mostly living with a result rather than watching it arrive.

The second is that the result itself carries risk. Visceral fat — the deep abdominal depot, not the layer you can pinch — increases with menopause and is an independent predictor of metabolic syndrome, diabetes and cardiovascular disease in women. In the SWAN fat-patterning study of 359 women aged 42–60 with CT-measured visceral fat, bioavailable testosterone was associated with that depot independently of age, race, total body fat and other cardiovascular risk factors, and the association survived adjustment for insulin resistance². The post-menopausal shift toward relative androgen predominance is doing something structural, not cosmetic.

What the drugs do, and the one study that asked whether menopause changes it

The primary trial averages above are not menopause-specific estimates. A later post hoc analysis from the SURMOUNT program did examine tirzepatide response by reproductive stage and found weight reduction across stages⁸. It was manufacturer-funded and does not replace a dedicated menopause trial. A separate small study compared semaglutide-treated women before and after menopause. Over four months on semaglutide 1 mg, postmenopausal women started heavier than premenopausal ones (95 ± 23.4 vs. 86.4 ± 12.8 kg) with more fat mass (45.2 ± 17.1 vs. 38.2 ± 9.8 kg) — but lost a statistically indistinguishable amount: 5.8 ± 4.7% versus 5.1 ± 3.2% of body weight (p = 0.4), with fat-mass loss of 4.1 ± 4.5 versus 3.1 ± 3.7 kg (p = 0.3) and lean-mass loss of 0.4 ± 1.7 versus 1.1 ± 3.7 kg (p = 0.1)⁶.

Be careful how you read that. In a study this small, "no significant difference" means a difference was not detected — not that none exists. It adds a small semaglutide comparison to the broader evidence, but it does not establish that menopausal status has no effect on response.

The cardiovascular result, and what it does not say

Heart risk climbs for women after midlife, which is why the conversation here is about more than the scale. SELECT randomized 17,604 adults with overweight or obesity and established cardiovascular disease but without diabetes; a primary cardiovascular endpoint event occurred in 6.5% on semaglutide 2.4 mg versus 8.0% on placebo, hazard ratio 0.80 (95% CI 0.72 to 0.90), over a mean 39.8 months of follow-up⁵. Discontinuation for adverse events ran 16.6% versus 8.2%, so the tolerability cost was real.

The limit is the enrollment criterion. Everyone in SELECT already had cardiovascular disease. That is a secondary-prevention population, and a post-menopausal woman without established disease should not read that hazard ratio as her own. It is the reason clinicians take midlife metabolic health seriously; it is not a menopause result.

The hormone-therapy gap, stated plainly

No randomized trial has tested a GLP-1 alongside menopausal hormone therapy, in either direction — not whether hormone therapy changes the weight response, not whether the GLP-1 changes anything about the hormone therapy. One retrospective cohort has looked, and is unpacked on taking a GLP-1 and hormone therapy at the same time; it is sixteen exposed women and cannot carry a recommendation. Beyond it, a 2026 scoping review of GLP-1 receptor agonists in menopausal and postmenopausal women opens by stating that their effects in this group "are not well characterized and may differ from other patient populations, given their different hormone profiles," finds the literature on central adiposity, vasomotor symptoms and cardiovascular markers limited, and closes by calling for larger, more robust studies in menopausal women⁷.

Practically, that makes coordination between whoever prescribes your GLP-1 and whoever manages your hormone therapy a judgment call between clinicians rather than a protocol either of them can look up. Ask them to talk to each other, and treat any "menopause weight-loss shot" marketed on top of this gap as marketing.

Where this sits on the evidence scale

Body composition and visceral fat after menopause: strong. Longitudinal DXA and CT imaging in a large multi-ethnic cohort, consistent across analyses.

Weight loss with these drugs at this age: strong overall, with more limited stage-specific evidence. Large placebo-controlled trials establish weight reduction. A later reproductive-stage analysis adds tirzepatide subgroup evidence⁸, without making the original trials dedicated menopause studies.

Whether menopause changes the response: limited. The four-month semaglutide comparison was small, while the SURMOUNT reproductive-stage analysis was post hoc^6,8. Together they are useful but cannot settle every question about stage-specific treatment.

GLP-1 alongside hormone therapy: very low. One retrospective cohort of 106 post-menopausal women — sixteen of them on hormone therapy — found a larger weight-loss response among the hormone-therapy users, in two groups that differed at baseline in exactly the directions that would produce that result anyway. No randomized trial, and a 2026 review of this exact population found the field thin and asked for trials. Unpacked on taking a GLP-1 and hormone therapy at the same time.

Cardiovascular benefit: strong in secondary prevention, unestablished otherwise. SELECT is a real result in people who already had heart disease, and says nothing about a healthy post-menopausal woman's absolute risk.

To weigh the two molecules, read semaglutide vs tirzepatide for mothers.